A prospective, randomized, open-label, comparative clinical trial in post-surgical melanoma patients with either DNP-modified autologous tumor vaccine or interferon alpha-2b

Trial Profile

A prospective, randomized, open-label, comparative clinical trial in post-surgical melanoma patients with either DNP-modified autologous tumor vaccine or interferon alpha-2b

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Melanoma vaccine (Primary) ; BCG; Cyclophosphamide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors AVAX Technologies
  • Most Recent Events

    • 10 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top